Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study
BackgroundIdiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.861419/full |
| _version_ | 1811234769661329408 |
|---|---|
| author | Sabina Oreska Sabina Oreska Hana Storkanova Hana Storkanova Jaroslav Kudlicka Vladimir Tuka Ondrej Mikes Zdislava Krupickova Martin Satny Eva Chytilova Jan Kvasnicka Maja Spiritovic Maja Spiritovic Barbora Hermankova Petr Cesak Marian Rybar Karel Pavelka Karel Pavelka Ladislav Senolt Ladislav Senolt Herman Mann Herman Mann Jiri Vencovsky Jiri Vencovsky Michal Vrablik Michal Tomcik Michal Tomcik |
| author_facet | Sabina Oreska Sabina Oreska Hana Storkanova Hana Storkanova Jaroslav Kudlicka Vladimir Tuka Ondrej Mikes Zdislava Krupickova Martin Satny Eva Chytilova Jan Kvasnicka Maja Spiritovic Maja Spiritovic Barbora Hermankova Petr Cesak Marian Rybar Karel Pavelka Karel Pavelka Ladislav Senolt Ladislav Senolt Herman Mann Herman Mann Jiri Vencovsky Jiri Vencovsky Michal Vrablik Michal Tomcik Michal Tomcik |
| author_sort | Sabina Oreska |
| collection | DOAJ |
| description | BackgroundIdiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features.MethodsThirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications.ResultsCompared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure.ConclusionsNo significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM. |
| first_indexed | 2024-04-12T11:42:18Z |
| format | Article |
| id | doaj.art-c03b7dda6090431296d9101b5754bdec |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T11:42:18Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-c03b7dda6090431296d9101b5754bdec2022-12-22T03:34:36ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-05-01910.3389/fmed.2022.861419861419Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional StudySabina Oreska0Sabina Oreska1Hana Storkanova2Hana Storkanova3Jaroslav Kudlicka4Vladimir Tuka5Ondrej Mikes6Zdislava Krupickova7Martin Satny8Eva Chytilova9Jan Kvasnicka10Maja Spiritovic11Maja Spiritovic12Barbora Hermankova13Petr Cesak14Marian Rybar15Karel Pavelka16Karel Pavelka17Ladislav Senolt18Ladislav Senolt19Herman Mann20Herman Mann21Jiri Vencovsky22Jiri Vencovsky23Michal Vrablik24Michal Tomcik25Michal Tomcik26Institute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, CzechiaDepartment of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, CzechiaDepartment of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, CzechiaFaculty of Mathematics and Physics, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czechia3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, CzechiaInstitute of Rheumatology, Prague, CzechiaDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, CzechiaBackgroundIdiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid therapy, all of which can lead to metabolism disturbances, atherogenesis, and increased cardiovascular (CV) risk. The aim of this study was to assess the CV risk in IIM patients and healthy controls (HC), and its association with disease-specific features.MethodsThirty nine patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis: n = 16, polymyositis: n = 7, immune-mediated necrotizing myopathy: n = 8, anti-synthetase syndrome: n = 8) and 39 age-/sex-matched HC (32 females, mean age 56) without rheumatic diseases were included. In both groups, subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded. Muscle involvement, disease activity, and tissue damage were evaluated (Manual Muscle Test-8, Myositis Intention to Treat Activity Index, Myositis Damage Index). Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (by densitometry and bioelectric impedance). The risk of fatal CV events was evaluated by the Systematic COronary Risk Evaluation (SCORE, charts for the European population) and its modifications.ResultsCompared to HC, there was no significant difference in IIM patients regarding blood pressure, ABI, PWV, CIMT, and the risk of fatal CV events by SCORE or SCORE2, or subclinical atherosclerosis (CIMT, carotid plaques, ABI, and PWV). The calculated CV risk scores by SCORE, SCORE2, and SCORE multiplied by the coefficient 1.5 (mSCORE) were reclassified according to the results of carotid plaque presence and CIMT; however, none of them was demonstrated to be significantly more accurate. Other significant predictors of CV risk in IIM patients included age, disease duration and activity, systemic inflammation, lipid profile, lean body mass, and blood pressure.ConclusionsNo significant differences in CV risk factors between our IIM patients and HC were observed. However, in IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition. None of the currently available scoring tools (SCORE, SCORE2, mSCORE) used in this study seems more accurate in estimating CV risk in IIM.https://www.frontiersin.org/articles/10.3389/fmed.2022.861419/fullatherosclerosismyositisinflammationcardiovascular riskrisk assessment |
| spellingShingle | Sabina Oreska Sabina Oreska Hana Storkanova Hana Storkanova Jaroslav Kudlicka Vladimir Tuka Ondrej Mikes Zdislava Krupickova Martin Satny Eva Chytilova Jan Kvasnicka Maja Spiritovic Maja Spiritovic Barbora Hermankova Petr Cesak Marian Rybar Karel Pavelka Karel Pavelka Ladislav Senolt Ladislav Senolt Herman Mann Herman Mann Jiri Vencovsky Jiri Vencovsky Michal Vrablik Michal Tomcik Michal Tomcik Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study Frontiers in Medicine atherosclerosis myositis inflammation cardiovascular risk risk assessment |
| title | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
| title_full | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
| title_fullStr | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
| title_full_unstemmed | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
| title_short | Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study |
| title_sort | cardiovascular risk in myositis patients compared to the general population preliminary data from a single center cross sectional study |
| topic | atherosclerosis myositis inflammation cardiovascular risk risk assessment |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.861419/full |
| work_keys_str_mv | AT sabinaoreska cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT sabinaoreska cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT hanastorkanova cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT hanastorkanova cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT jaroslavkudlicka cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT vladimirtuka cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT ondrejmikes cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT zdislavakrupickova cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT martinsatny cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT evachytilova cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT jankvasnicka cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT majaspiritovic cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT majaspiritovic cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT barborahermankova cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT petrcesak cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT marianrybar cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT karelpavelka cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT karelpavelka cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT ladislavsenolt cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT ladislavsenolt cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT hermanmann cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT hermanmann cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT jirivencovsky cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT jirivencovsky cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT michalvrablik cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT michaltomcik cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy AT michaltomcik cardiovascularriskinmyositispatientscomparedtothegeneralpopulationpreliminarydatafromasinglecentercrosssectionalstudy |